|
Nov 8
|
ASX Growth Companies With High Insider Ownership Seeing Up To 61% Earnings Growth
|
|
Nov 6
|
Three High Growth Tech Stocks in Australia
|
|
Oct 4
|
ASX Growth Companies With High Insider Ownership In October 2024
|
|
Oct 3
|
ASX Growth Companies With High Insider Ownership October 2024
|
|
Oct 2
|
3 High Growth ASX Stocks With Significant Insider Ownership
|
|
Oct 1
|
Top High Growth Tech Stocks To Watch In Australia October 2024
|
|
Sep 30
|
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
|
|
Jul 31
|
Mesoblast Insiders Land Bargain With Gains Of US$58m
|
|
Jul 31
|
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
|
|
Jul 23
|
FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
|
|
Jul 23
|
FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
|
|
Jun 18
|
ASX Growth Companies With High Insider Ownership To Watch In June 2024
|
|
Jun 17
|
Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120%
|
|
Jun 14
|
High Insider Ownership Growth Stocks On The ASX In June 2024
|
|
Jun 13
|
Exploring Three ASX Growth Companies With Significant Insider Ownership
|
|
Apr 30
|
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
|
|
Apr 26
|
Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%
|
|
Mar 27
|
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
|
|
Mar 26
|
After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant
|
|
Mar 26
|
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
|